Technical Analysis for KALA - Kala Pharmaceuticals, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| See historical KALA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Mar 22 | 50 DMA Support | Bullish | 0.00% |
| Mar 22 | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% |
| Mar 22 | Bollinger Band Squeeze | Range Contraction | 0.00% |
| Mar 22 | Lower Bollinger Band Walk | Weakness | 0.00% |
| Mar 22 | BB Squeeze + Lower Band Touch | Range Contraction | 0.00% |
| Mar 22 | Below Lower BB | Weakness | 0.00% |
| Mar 22 | Down 3 Days in a Row | Weakness | 0.00% |
| Mar 22 | Down 4 Days in a Row | Weakness | 0.00% |
| Mar 22 | Down 5 Days in a Row | Weakness | 0.00% |
| Mar 22 | Lower Bollinger Band Touch | Weakness | 0.00% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-03-11
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
Kala Pharmaceuticals Inc. is a United States-based company that is developing ophthalmic treatments based on the Company’s Mucosal Penetrating Product (MPP) platform. The Company’s topical ocular MPP formulations enhance penetration of diverse therapeutic agents into ocular tissue, including those in the back of the eye, by facilitating penetration through the mucus layer of tear film. Its product development pipeline includes a 1% formulation of loteprednol etabonate to treat post-surgical ocular inflammation and pain; a 0.25% LE-MPP formulation for dry eye, blepharitis, and retinal disease, and a topically applied receptor tyrosine kinase inhibitir (RTKi-MPP) for the treatment of wet age-related macular degeneration (AMD).
Medicine Medical Specialties Pain Organ Systems Macular Degeneration Wet Age Related Macular Degeneration Glucocorticoids Retinal Disease Post Surgical Ocular Inflammation
Medicine Medical Specialties Pain Organ Systems Macular Degeneration Wet Age Related Macular Degeneration Glucocorticoids Retinal Disease Post Surgical Ocular Inflammation
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more KALA news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 18.07 |
| 52 Week Low | 4.03 |
| Average Volume | 232,657 |
| 200-Day Moving Average | 9.24 |
| 50-Day Moving Average | 7.1898 |
| 20-Day Moving Average | 8.3355 |
| 10-Day Moving Average | 8.234 |
| Average True Range | 0.5466 |
| ADX | 28.25 |
| +DI | 18.6553 |
| -DI | 26.9171 |
| Chandelier Exit (Long, 3 ATRs ) | 7.6102 |
| Chandelier Exit (Short, 3 ATRs ) | 8.7798 |
| Upper Bollinger Band | 9.0444 |
| Lower Bollinger Band | 7.6266 |
| Percent B (%b) | -0.15 |
| BandWidth | 17.009178 |
| MACD Line | 0.1755 |
| MACD Signal Line | 0.3513 |
| MACD Histogram | -0.1758 |
| Fundamentals | Value |
|---|---|
| Market Cap | 179.76 Million |
| Num Shares | 24.2 Million |
| EPS | -32.85 |
| Price-to-Earnings (P/E) Ratio | -0.23 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 0.00 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.37 | ||||
| Resistance 3 (R3) | 8.38 | 8.07 | 8.21 | ||
| Resistance 2 (R2) | 8.07 | 7.83 | 8.07 | 8.15 | |
| Resistance 1 (R1) | 7.75 | 7.68 | 7.60 | 7.74 | 8.10 |
| Pivot Point | 7.44 | 7.44 | 7.37 | 7.44 | 7.44 |
| Support 1 (S1) | 7.12 | 7.20 | 6.97 | 7.11 | 6.74 |
| Support 2 (S2) | 6.81 | 7.05 | 6.81 | 6.69 | |
| Support 3 (S3) | 6.49 | 6.81 | 6.63 | ||
| Support 4 (S4) | 6.48 |
